News
05-04-2010, 08:20 AM
Cost-utility analyses of new biotechnologies are often conducted under best-practice hypotheses; there exists a need to examine the robustness of these analyses in the real-health practice setting. Oncotype DX® (Genomic Health, Inc...
More... (http://mnt.to/f/3C72)
More... (http://mnt.to/f/3C72)